34
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Zika virus (ZIKV) emerged on a global scale and no licensed vaccine ensures long-lasting anti-ZIKV immunity. Here we report the design and comparative evaluation of four replication-deficient chimpanzee adenoviral (ChAdOx1) ZIKV vaccine candidates comprising the addition or deletion of precursor membrane (prM) and envelope, with or without its transmembrane domain (TM). A single, non-adjuvanted vaccination of ChAdOx1 ZIKV vaccines elicits suitable levels of protective responses in mice challenged with ZIKV. ChAdOx1 prME ∆TM encoding prM and envelope without TM provides 100% protection, as well as long-lasting anti-envelope immune responses and no evidence of in vitro antibody-dependent enhancement to dengue virus. Deletion of prM and addition of TM reduces protective efficacy and yields lower anti-envelope responses. Our finding that immunity against ZIKV can be enhanced by modulating antigen membrane anchoring highlights important parameters in the design of viral vectored ZIKV vaccines to support further clinical assessments.

          Abstract

          Zika virus (ZIKV) is an emerging global health issue, but currently no licensed vaccine achieves lasting protective immunity. Here the authors show that a ZIKV vaccine containing the envelop protein without the transmembrane domain and the precursor membrane protein can provide effective protection in mouse models.

          Related collections

          Most cited references25

          • Record: found
          • Abstract: found
          • Article: not found

          Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys.

          Zika virus (ZIKV) is responsible for a major ongoing epidemic in the Americas and has been causally associated with fetal microcephaly. The development of a safe and effective ZIKV vaccine is therefore an urgent global health priority. Here we demonstrate that three different vaccine platforms protect against ZIKV challenge in rhesus monkeys. A purified inactivated virus vaccine induced ZIKV-specific neutralizing antibodies and completely protected monkeys against ZIKV strains from both Brazil and Puerto Rico. Purified immunoglobulin from vaccinated monkeys also conferred passive protection in adoptive transfer studies. A plasmid DNA vaccine and a single-shot recombinant rhesus adenovirus serotype 52 vector vaccine, both expressing ZIKV premembrane and envelope, also elicited neutralizing antibodies and completely protected monkeys against ZIKV challenge. These data support the rapid clinical development of ZIKV vaccines for humans.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Vaginal Exposure to Zika Virus during Pregnancy Leads to Fetal Brain Infection.

            Zika virus (ZIKV) can be transmitted sexually between humans. However, it is unknown whether ZIKV replicates in the vagina and impacts the unborn fetus. Here, we establish a mouse model of vaginal ZIKV infection and demonstrate that, unlike other routes, ZIKV replicates within the genital mucosa even in wild-type (WT) mice. Mice lacking RNA sensors or transcription factors IRF3 and IRF7 resulted in higher levels of local viral replication. Furthermore, mice lacking the type I interferon (IFN) receptor (IFNAR) became viremic and died of infection after a high-dose vaginal ZIKV challenge. Notably, vaginal infection of pregnant dams during early pregnancy led to fetal growth restriction and infection of the fetal brain in WT mice. This was exacerbated in mice deficient in IFN pathways, leading to abortion. Our study highlights the vaginal tract as a highly susceptible site of ZIKV replication and illustrates the dire disease consequences during pregnancy.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Rapid development of a DNA vaccine for Zika virus.

              Zika virus (ZIKV) was identified as a cause of congenital disease during the explosive outbreak in the Americas and Caribbean that began in 2015. Because of the ongoing fetal risk from endemic disease and travel-related exposures, a vaccine to prevent viremia in women of childbearing age and their partners is imperative. We found that vaccination with DNA expressing the premembrane and envelope proteins of ZIKV was immunogenic in mice and nonhuman primates, and protection against viremia after ZIKV challenge correlated with serum neutralizing activity. These data not only indicate that DNA vaccination could be a successful approach to protect against ZIKV infection, but also suggest a protective threshold of vaccine-induced neutralizing activity that prevents viremia after acute infection.
                Bookmark

                Author and article information

                Contributors
                arturo.reyes@ndm.ox.ac.uk
                Journal
                Nat Commun
                Nat Commun
                Nature Communications
                Nature Publishing Group UK (London )
                2041-1723
                22 June 2018
                22 June 2018
                2018
                : 9
                : 2441
                Affiliations
                [1 ]The Jenner Institute, Nuffield Department of Medicine, University of Oxford, The Henry Wellcome Building for Molecular Physiology, Roosevelt Drive, Oxford, OX3 7BN UK
                [2 ]ISNI 000000041936754X, GRID grid.38142.3c, Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, , Harvard Medical School, ; Boston, MA 02215 USA
                [3 ]ISNI 0000 0001 2113 8111, GRID grid.7445.2, Division of Immunology and Inflammation, Department of Medicine, Hammersmith Campus, , Imperial College London, ; London, W12 0NN UK
                [4 ]ISNI 0000 0004 1936 8948, GRID grid.4991.5, Nuffield Department of Medicine and Oxford NIHR Biomedical Research Centre, , University of Oxford, ; Oxford, OX3 7FZ UK
                [5 ]ISNI 0000 0001 2193 314X, GRID grid.8756.c, MRC-University of Glasgow Centre for Virus Research, , University of Glasgow, ; Glasgow,, G61 1QH Scotland UK
                [6 ]ISNI 0000 0001 0723 0931, GRID grid.418068.3, Aggeu Magalhães Institute, , Oswaldo Cruz Foundation, ; 50670-465 Recife, Brazil
                [7 ]ISNI 0000 0004 1936 8948, GRID grid.4991.5, The Jenner Institute, Nuffield Department of Medicine, , University of Oxford, ; Old Road Campus Research Building, Roosevelt Drive, Oxford, OX3 7DQ UK
                [8 ]ISNI 0000 0004 1937 0490, GRID grid.10223.32, Dengue Hemorrhagic Fever Research Unit, Office for Research and Development, Faculty of Medicine Siriraj Hospital, , Mahidol University, ; Bangkok, 10700 Thailand
                [9 ]ISNI 0000 0004 1936 8948, GRID grid.4991.5, Division of Medical Sciences, John Radcliffe Hospital, , University of Oxford, ; Oxford, OX3 9DU UK
                Author information
                http://orcid.org/0000-0001-7932-2341
                http://orcid.org/0000-0003-1978-088X
                http://orcid.org/0000-0002-9995-1804
                http://orcid.org/0000-0001-6716-442X
                http://orcid.org/0000-0002-3983-8025
                http://orcid.org/0000-0002-1111-0825
                http://orcid.org/0000-0003-2847-9407
                http://orcid.org/0000-0002-4370-0707
                http://orcid.org/0000-0002-6823-9750
                http://orcid.org/0000-0003-4600-2047
                http://orcid.org/0000-0003-0900-9629
                http://orcid.org/0000-0002-2648-1696
                Article
                4859
                10.1038/s41467-018-04859-5
                6015009
                29934593
                3c566584-1f64-47de-90c1-400c2347157e
                © The Author(s) 2018

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 11 January 2017
                : 23 May 2018
                Funding
                Funded by: FundRef https://doi.org/10.13039/501100006041, Innovate UK;
                Award ID: 972216
                Award Recipient :
                Categories
                Article
                Custom metadata
                © The Author(s) 2018

                Uncategorized
                Uncategorized

                Comments

                Comment on this article